| NCT04459416 |
Managing Pain Caused by Chemotherapy in People With Myeloma or Lymphoma |
https://ClinicalTrials.gov/show/NCT04459416 |
Recruiting |
Memorial Sloan Kettering Cancer Center |
2023-06-30 |
| NCT04318080 |
Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT04318080 |
Recruiting |
BeiGene |
2022-10-31 |
| NCT03947255 |
A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03947255 |
Recruiting |
Seattle Genetics, Inc. |
2024-12-31 |
| NCT03907488 |
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT03907488 |
Recruiting |
National Cancer Institute (NCI) |
2024-03-01 |
| NCT03755414 |
Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation |
https://ClinicalTrials.gov/show/NCT03755414 |
Recruiting |
Washington University School of Medicine |
2022-06-30 |
| NCT03646123 |
Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT03646123 |
Recruiting |
Seattle Genetics, Inc. |
2022-07-07 |
| NCT03407144 |
Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667) |
https://ClinicalTrials.gov/show/NCT03407144 |
Recruiting |
Merck Sharp & Dohme Corp. |
2027-02-13 |
| NCT03343665 |
Treatment With Nivolumab at the Fixed Dose 40 mg (Nivo40) in Patients With Relapsed/Refractory Hodgkins Lymphoma |
https://ClinicalTrials.gov/show/NCT03343665 |
Completed |
St. Petersburg State Pavlov Medical University |
2019-12-20 |
| NCT03343652 |
A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT03343652 |
Completed |
St. Petersburg State Pavlov Medical University |
2019-03-27 |
| NCT03337919 |
ANIMATE: Phase II Study of Nivolumab Monotherapy for Relapsed/Refractory Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT03337919 |
Recruiting |
University College, London |
2022-05-31 |
| NCT03331341 |
Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT03331341 |
Recruiting |
University of Washington |
2021-12-01 |
| NCT03250962 |
SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT03250962 |
Recruiting |
Chinese PLA General Hospital |
2022-07-21 |
| NCT03236935 |
Phase Ib of L-NMMA and Pembrolizumab |
https://ClinicalTrials.gov/show/NCT03236935 |
Recruiting |
The Methodist Hospital System |
2020-01-01 |
| NCT03233347 |
Doxorubicin Hydrochloride, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT03233347 |
Recruiting |
Academic and Community Cancer Research United |
2023-08-01 |
| NCT03226249 |
PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT03226249 |
Active, not recruiting |
Northwestern University |
2020-08-01 |
| NCT03209973 |
A Study of BGB-A317 as Monotherapy in Relapsed or Refractory Classical Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT03209973 |
Active, not recruiting |
BeiGene |
2018-07-23 |
| NCT03179917 |
Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT03179917 |
Recruiting |
Memorial Sloan Kettering Cancer Center |
2021-06-30 |
| NCT03159897 |
FIL Study on ABVD DD-DI as Upfront Therapy in HL. |
https://ClinicalTrials.gov/show/NCT03159897 |
Recruiting |
Fondazione Italiana Linfomi ONLUS |
2023-01-31 |
| NCT03154710 |
Relevance of a Web-mediated Follow up in Patients Having a Lymphoma With a High Risk of Relapse in Complete or Partial Response |
https://ClinicalTrials.gov/show/NCT03154710 |
Recruiting |
Weprom |
2022-01-31 |
| NCT03150329 |
Pembrolizumab and Vorinostat in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, or Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT03150329 |
Recruiting |
City of Hope Medical Center |
2020-07-18 |
| NCT03138499 |
A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant, |
https://ClinicalTrials.gov/show/NCT03138499 |
Active, not recruiting |
Bristol-Myers Squibb |
2020-11-29 |
| NCT03125642 |
Auto Stem Cell Transplant for Lymphoma Patients |
https://ClinicalTrials.gov/show/NCT03125642 |
Recruiting |
Masonic Cancer Center, University of Minnesota |
2023-04-30 |
| NCT03114683 |
Efficacy and Safety Evaluation of IBI308 in Treatment of Patients With Relapsed/Refractory Classical Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT03114683 |
Completed |
Innovent Biologics (Suzhou) Co. Ltd. |
2018-12-30 |
| NCT03107663 |
â¸â¹Zr-Df-IAB22M2C PET/CT in Patients With Selected Solid Malignancies or Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT03107663 |
Completed |
ImaginAb, Inc. |
2018-08-16 |
| NCT03077828 |
Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT03077828 |
Recruiting |
Northwestern University |
2022-11-30 |
| NCT03057795 |
Nivolumab and Brentuximab Vedotin After Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Classical Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT03057795 |
Recruiting |
City of Hope Medical Center |
2020-10-08 |
| NCT03049449 |
T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas |
https://ClinicalTrials.gov/show/NCT03049449 |
Recruiting |
National Institutes of Health Clinical Center (CC) |
2021-06-30 |
| NCT03044743 |
PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies |
https://ClinicalTrials.gov/show/NCT03044743 |
Recruiting |
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
2020-03-31 |
| NCT03038672 |
Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas |
https://ClinicalTrials.gov/show/NCT03038672 |
Recruiting |
National Cancer Institute (NCI) |
2020-12-31 |
| NCT03033914 |
A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL) |
https://ClinicalTrials.gov/show/NCT03033914 |
Recruiting |
Memorial Sloan Kettering Cancer Center |
2021-01-31 |
| NCT03016871 |
Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL |
https://ClinicalTrials.gov/show/NCT03016871 |
Recruiting |
City of Hope Medical Center |
2021-06-22 |
| NCT03013933 |
Brentuximab Vedotin, Cyclosporine, and Verapamil Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT03013933 |
Recruiting |
City of Hope Medical Center |
2020-08-26 |
| NCT03004833 |
Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT03004833 |
Active, not recruiting |
University of Cologne |
2020-12-31 |
| NCT02996773 |
Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine |
https://ClinicalTrials.gov/show/NCT02996773 |
Recruiting |
University of Arizona |
2022-11-29 |
| NCT02981914 |
Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT02981914 |
Recruiting |
University of Chicago |
2023-02-28 |
| NCT02979522 |
A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT02979522 |
Active, not recruiting |
Takeda |
2020-06-30 |
| NCT02973113 |
Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE) |
https://ClinicalTrials.gov/show/NCT02973113 |
Active, not recruiting |
Baylor College of Medicine |
2021-04-16 |
| NCT02940301 |
Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT02940301 |
Recruiting |
Ohio State University Comprehensive Cancer Center |
2020-05-31 |
| NCT02939014 |
Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL) |
https://ClinicalTrials.gov/show/NCT02939014 |
Completed |
Takeda |
2018-08-02 |
| NCT02875067 |
Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT02875067 |
Completed |
NYU Langone Health |
2017-10-02 |
| NCT02869633 |
Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT02869633 |
Active, not recruiting |
Vanderbilt-Ingram Cancer Center |
2021-10-31 |
| NCT02824029 |
Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT02824029 |
Recruiting |
Barbara Ann Karmanos Cancer Institute |
2019-04-30 |
| NCT02815137 |
Detection and Prognostic Value of Recurrent XPO1 Mutations of Patients With Classical Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT02815137 |
Recruiting |
Centre Henri Becquerel |
2018-12-31 |
| NCT02797717 |
Treatment for Classical Hodgkin Lymphoma in Children and Adolescents |
https://ClinicalTrials.gov/show/NCT02797717 |
Recruiting |
Rabin Medical Center |
2022-12-31 |
| NCT02797470 |
Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT02797470 |
Recruiting |
AIDS Malignancy Consortium |
2021-09-30 |
| NCT02758717 |
Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT02758717 |
Active, not recruiting |
Academic and Community Cancer Research United |
2019-08-13 |
| NCT02686346 |
Brentuximab Vedotin in Refractory/Relapsed Hodgkin Lymphoma Treated by ICE |
https://ClinicalTrials.gov/show/NCT02686346 |
Active, not recruiting |
The Lymphoma Academic Research Organisation |
2018-10-31 |
| NCT02684708 |
Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents |
https://ClinicalTrials.gov/show/NCT02684708 |
Recruiting |
University of Giessen |
2026-09-30 |
| NCT02684292 |
Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204) |
https://ClinicalTrials.gov/show/NCT02684292 |
Active, not recruiting |
Merck Sharp & Dohme Corp. |
2023-12-30 |
| NCT03213665 |
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) |
https://ClinicalTrials.gov/show/NCT03213665 |
Recruiting |
National Cancer Institute (NCI) |
2024-09-30 |
| NCT02665650 |
Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT02665650 |
Completed |
Affimed GmbH |
2019-01-31 |
| NCT02663297 |
Administration of T Lymphocytes for Prevention of Relapse of Lymphomas |
https://ClinicalTrials.gov/show/NCT02663297 |
Recruiting |
UNC Lineberger Comprehensive Cancer Center |
2021-09-30 |
| NCT02661503 |
HD21 for Advanced Stages |
https://ClinicalTrials.gov/show/NCT02661503 |
Recruiting |
University of Cologne |
2020-06-30 |
| NCT02639559 |
Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT02639559 |
Active, not recruiting |
Washington University School of Medicine |
2018-04-12 |
| NCT02626884 |
Ibrutinib in Relapsed Nodular Lymphocyte-predominant Hodgkin Lymphoma (NLPHL) |
https://ClinicalTrials.gov/show/NCT02626884 |
Active, not recruiting |
University of Cologne |
2020-12-31 |
| NCT01896999 |
Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01896999 |
Recruiting |
National Cancer Institute (NCI) |
2025-03-20 |
| NCT01087294 |
Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT01087294 |
Recruiting |
National Institutes of Health Clinical Center (CC) |
2023-03-01 |
| NCT02576496 |
Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT02576496 |
Recruiting |
Mundipharma-EDO GmbH |
2021-03-31 |
| NCT02595866 |
Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms |
https://ClinicalTrials.gov/show/NCT02595866 |
Recruiting |
National Cancer Institute (NCI) |
2021-07-01 |
| NCT02572167 |
A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT02572167 |
Active, not recruiting |
Seattle Genetics, Inc. |
2018-03-01 |
| NCT02376699 |
Safety Study of SEA-CD40 in Cancer Patients |
https://ClinicalTrials.gov/show/NCT02376699 |
Recruiting |
Seattle Genetics, Inc. |
2021-10-31 |
| NCT01716806 |
A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) |
https://ClinicalTrials.gov/show/NCT01716806 |
Recruiting |
Seattle Genetics, Inc. |
2021-09-30 |
| NCT02568553 |
Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT02568553 |
Recruiting |
National Cancer Institute (NCI) |
2020-12-31 |
| NCT02567851 |
A Study of Brentuximab Vedotin in Patients With Hodgkin Lymphoma Unsuitable for Chemotherapy Due to Age, Frailty or Co-morbidity |
https://ClinicalTrials.gov/show/NCT02567851 |
Completed |
University of Birmingham |
2016-01-14 |
| NCT01100502 |
A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial) |
https://ClinicalTrials.gov/show/NCT01100502 |
Completed |
Seattle Genetics, Inc. |
2014-08-31 |
| NCT02526823 |
Clinical Application of Polyethylene Glycol Liposome Doxorubicin (PLD) in Primary Lymphoma |
https://ClinicalTrials.gov/show/NCT02526823 |
Recruiting |
Shandong Provincial Hospital |
2019-12-31 |
| NCT02505269 |
Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT02505269 |
Active, not recruiting |
Massachusetts General Hospital |
2019-06-30 |
| NCT02467946 |
Hodgkin Lymphoma Treatment With Adcetris and Levact in the Old Patient |
https://ClinicalTrials.gov/show/NCT02467946 |
Active, not recruiting |
Centre Antoine Lacassagne |
2019-12-31 |
| NCT02453594 |
Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087) |
https://ClinicalTrials.gov/show/NCT02453594 |
Active, not recruiting |
Merck Sharp & Dohme Corp. |
2021-04-20 |
| NCT02432235 |
Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT02432235 |
Completed |
ADC Therapeutics S.A. |
2019-10-24 |
| NCT02429375 |
Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT02429375 |
Active, not recruiting |
Memorial Sloan Kettering Cancer Center |
2021-04-30 |
| NCT02414568 |
Bendamustine Study in Classical Hodgkin Lymphoma Patients Over 60 Treated by Prednisone, Vinblastine and Doxorubicin |
https://ClinicalTrials.gov/show/NCT02414568 |
Active, not recruiting |
The Lymphoma Academic Research Organisation |
2018-12-14 |
| NCT02398240 |
Brentuximab for Newly Diagnosed Hodgkin Disease |
https://ClinicalTrials.gov/show/NCT02398240 |
Recruiting |
New York Medical College |
2020-12-31 |
| NCT02396134 |
Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT02396134 |
Recruiting |
City of Hope Medical Center |
2020-05-31 |
| NCT02389101 |
Molecular and Whole-body MR Imaging in Lymphomas |
https://ClinicalTrials.gov/show/NCT02389101 |
Completed |
Turku University Hospital |
2016-03-31 |
| NCT02362997 |
Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL |
https://ClinicalTrials.gov/show/NCT02362997 |
Recruiting |
Dana-Farber Cancer Institute |
2020-09-30 |
| NCT02321592 |
GHSG-AFM13 An Open-label, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT02321592 |
Active, not recruiting |
University of Cologne |
2020-12-31 |
| NCT02304458 |
Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas |
https://ClinicalTrials.gov/show/NCT02304458 |
Active, not recruiting |
National Cancer Institute (NCI) |
2021-01-31 |
| NCT02298283 |
Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD |
https://ClinicalTrials.gov/show/NCT02298283 |
Active, not recruiting |
The Lymphoma Academic Research Organisation |
2020-08-31 |
| NCT02298257 |
A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage III-IV HIV-associated Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT02298257 |
Active, not recruiting |
The Lymphoma Academic Research Organisation |
2020-06-30 |
| NCT02292979 |
Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hodgkin Lymphoma. |
https://ClinicalTrials.gov/show/NCT02292979 |
Active, not recruiting |
The Lymphoma Academic Research Organisation |
2016-12-31 |
| NCT02287311 |
Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL) |
https://ClinicalTrials.gov/show/NCT02287311 |
Recruiting |
Baylor College of Medicine |
2021-02-28 |
| NCT02247869 |
Dose-dense ABVD First Line Therapy in Early Stage Unfavorable Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT02247869 |
Completed |
Fondazione Italiana Linfomi ONLUS |
2015-06-30 |
| NCT02244021 |
BRENTUXIMAB VEDOTIN as Pre-ASCT Induction Therapy in R/R HL Patients Non Responding to IGEV |
https://ClinicalTrials.gov/show/NCT02244021 |
Completed |
Fondazione Italiana Linfomi ONLUS |
2016-07-31 |
| NCT02243436 |
Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed or Refractory Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT02243436 |
Completed |
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea |
2019-01-31 |
| NCT02240719 |
Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT02240719 |
Completed |
University of California, Davis |
2018-04-09 |
| NCT02227433 |
Brentuximab Vedotin in the Elderly Hodgkin Lymphoma Patients at First Relapse or With Primary Refractory Disease. |
https://ClinicalTrials.gov/show/NCT02227433 |
Active, not recruiting |
Fondazione Italiana Linfomi ONLUS |
2018-04-03 |
| NCT02227199 |
Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT02227199 |
Active, not recruiting |
University of Washington |
2020-03-30 |
| NCT02213913 |
Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas |
https://ClinicalTrials.gov/show/NCT02213913 |
Recruiting |
University of Chicago |
2020-07-29 |
| NCT02191930 |
Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT02191930 |
Recruiting |
University of Cologne |
2018-12-31 |
| NCT02181738 |
Study of Nivolumab in Patients With Classical Hodgkin’s Lymphoma (Registrational) |
https://ClinicalTrials.gov/show/NCT02181738 |
Active, not recruiting |
Bristol-Myers Squibb |
2017-08-31 |
| NCT02181478 |
Intra-Osseous Co-Transplant of UCB and hMSC |
https://ClinicalTrials.gov/show/NCT02181478 |
Active, not recruiting |
Case Comprehensive Cancer Center |
2019-12-19 |
| NCT02181218 |
Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas |
https://ClinicalTrials.gov/show/NCT02181218 |
Active, not recruiting |
Washington University School of Medicine |
2019-03-28 |
| NCT02168140 |
CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT02168140 |
Active, not recruiting |
Wake Forest University Health Sciences |
2019-04-18 |
| NCT02166463 |
Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB or Stage IIIB-IVB Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT02166463 |
Active, not recruiting |
National Cancer Institute (NCI) |
2020-12-31 |
| NCT02164500 |
JAK-inhibition in Recurrent Classical Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT02164500 |
Completed |
University of Cologne |
2019-05-17 |
| NCT02164006 |
Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin’s Lymphoma Patients |
https://ClinicalTrials.gov/show/NCT02164006 |
Completed |
TG Therapeutics, Inc. |
2016-05-31 |
| NCT02104427 |
PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients |
https://ClinicalTrials.gov/show/NCT02104427 |
Completed |
TaiGen Biotechnology Co., Ltd. |
2015-11-30 |
| NCT02098512 |
Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients |
https://ClinicalTrials.gov/show/NCT02098512 |
Recruiting |
New York Medical College |
2019-12-31 |
| NCT02059239 |
Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma |
https://ClinicalTrials.gov/show/NCT02059239 |
Active, not recruiting |
Weill Medical College of Cornell University |
2019-12-16 |
| NCT01316146 |
Administration of T Lymphocytes for Hodgkin’s Lymphoma and Non-Hodgkin’s Lymphoma (CART CD30) |
https://ClinicalTrials.gov/show/NCT01316146 |
Active, not recruiting |
UNC Lineberger Comprehensive Cancer Center |
2016-01-28 |
| NCT01315132 |
A Study of Bone Marrow Transplantation Using Fully-Matched Relatives as Donors for Patients With Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT01315132 |
Completed |
Thomas Jefferson University |
2018-09-19 |
| NCT01304849 |
Use of Interim PET Scan to Modify Therapy in Advanced Hodgkin’s Lymphoma in Order to Improve Outcomes |
https://ClinicalTrials.gov/show/NCT01304849 |
Completed |
Cancer Institute WIA |
2013-09-30 |
| NCT01283776 |
Cyclophosphamide as Sole Graft-Versus-Host-Prophylaxis After Allogeneic Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT01283776 |
Completed |
University of Cologne |
2013-12-31 |
| NCT01273766 |
Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01273766 |
Completed |
Wake Forest University Health Sciences |
2012-03-31 |
| NCT03096782 |
Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma |
https://ClinicalTrials.gov/show/NCT03096782 |
Recruiting |
M.D. Anderson Cancer Center |
2020-10-31 |
| NCT01271127 |
Screening for Coronary Artery Disease After Mediastinal Irradiation |
https://ClinicalTrials.gov/show/NCT01271127 |
Completed |
Leiden University Medical Center |
2013-06-30 |
| NCT03800706 |
A Phase II Study to Evaluate the Safety and Efficacy of TQB2450 Injection in Relapsed or Refractory Classical Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT03800706 |
Recruiting |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2020-02-28 |
| NCT02003625 |
Meloxicam vs Placebo for Mobilization |
https://ClinicalTrials.gov/show/NCT02003625 |
Completed |
Massachusetts General Hospital |
2019-02-28 |
| NCT01998035 |
Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies |
https://ClinicalTrials.gov/show/NCT01998035 |
Active, not recruiting |
Columbia University |
2019-12-31 |
| NCT01990534 |
A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01990534 |
Completed |
Takeda |
2016-03-24 |
| NCT01969435 |
Study of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for Lymphoma |
https://ClinicalTrials.gov/show/NCT01969435 |
Completed |
Washington University School of Medicine |
2015-09-30 |
| NCT01965119 |
Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01965119 |
Completed |
Samsung Medical Center |
2017-06-30 |
| NCT01959477 |
Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT01959477 |
Completed |
Case Comprehensive Cancer Center |
2015-01-31 |
| NCT01956084 |
Cytotoxic T Cells to Treat Relapsed EBV-positive Lymphoma |
https://ClinicalTrials.gov/show/NCT01956084 |
Active, not recruiting |
Children’s National Research Institute |
2020-09-30 |
| NCT01951885 |
Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention |
https://ClinicalTrials.gov/show/NCT01951885 |
Recruiting |
Case Comprehensive Cancer Center |
2020-07-31 |
| NCT01950364 |
A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01950364 |
Completed |
Millennium Pharmaceuticals, Inc. |
2014-10-31 |
| NCT01947140 |
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies |
https://ClinicalTrials.gov/show/NCT01947140 |
Recruiting |
Columbia University |
2021-01-31 |
| NCT01921387 |
Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies |
https://ClinicalTrials.gov/show/NCT01921387 |
Active, not recruiting |
Fred Hutchinson Cancer Research Center |
2017-07-26 |
| NCT01920932 |
Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01920932 |
Active, not recruiting |
St. Jude Children’s Research Hospital |
2020-11-16 |
| NCT01902160 |
Temsirolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01902160 |
Completed |
National Cancer Institute (NCI) |
2015-05-31 |
| NCT01897012 |
Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas |
https://ClinicalTrials.gov/show/NCT01897012 |
Completed |
National Cancer Institute (NCI) |
2018-10-31 |
| NCT01877005 |
A Phase II Study of Oral JAK1/JAK2 Inhibitor INC424 in Adult Patients With Relapsed/Refractory Classical Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT01877005 |
Completed |
The Lymphoma Academic Research Organisation |
2015-06-30 |
| NCT01874054 |
Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01874054 |
Completed |
Seattle Genetics, Inc. |
2015-12-31 |
| NCT01868451 |
Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01868451 |
Active, not recruiting |
Memorial Sloan Kettering Cancer Center |
2020-05-31 |
| NCT01858922 |
Chemotherapy With or Without Radiation, Low and Intermediate Risk Hodgkins Lymphoma, TXCH-HD-12A |
https://ClinicalTrials.gov/show/NCT01858922 |
Active, not recruiting |
Baylor College of Medicine |
2020-06-30 |
| NCT01854567 |
P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01854567 |
Completed |
Mesoblast, Ltd. |
2016-09-23 |
| NCT01839916 |
Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01839916 |
Completed |
University of Chicago |
2018-08-31 |
| NCT01833884 |
Kinetic of Cytokines Decrease and Hodgkin Lymphoma Prognostic |
https://ClinicalTrials.gov/show/NCT01833884 |
Completed |
Centre Henri Becquerel |
2016-05-31 |
| NCT01805037 |
Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas |
https://ClinicalTrials.gov/show/NCT01805037 |
Active, not recruiting |
Northwestern University |
2021-01-31 |
| NCT01789255 |
Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT01789255 |
Completed |
National Cancer Institute (NCI) |
2014-03-31 |
| NCT01771107 |
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01771107 |
Active, not recruiting |
National Cancer Institute (NCI) |
2021-10-16 |
| NCT01768845 |
Unrelated Umbilical Cord Blood (UBC)Transplantation |
https://ClinicalTrials.gov/show/NCT01768845 |
Active, not recruiting |
West Virginia University |
2019-05-14 |
| NCT01764230 |
Prevention of Ovarian Function Damage by a GnRH Analogue During Chemotherapy in Hodgkin Lymphoma Patients |
https://ClinicalTrials.gov/show/NCT01764230 |
Completed |
Masaryk University |
2007-07-31 |
| NCT01760655 |
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01760655 |
Recruiting |
Thomas Jefferson University |
2021-03-31 |
| NCT01748721 |
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma |
https://ClinicalTrials.gov/show/NCT01748721 |
Completed |
Morphotek |
2015-05-31 |
| NCT01712490 |
A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01712490 |
Active, not recruiting |
Takeda |
2017-04-20 |
| NCT01703949 |
Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma |
https://ClinicalTrials.gov/show/NCT01703949 |
Recruiting |
University of Washington |
2021-01-15 |
| NCT01702961 |
Rituxan + BEAM and Auto Stem Cell Transplant for High Risk Lymphoma or Hodgkin’s Disease |
https://ClinicalTrials.gov/show/NCT01702961 |
Completed |
Baylor College of Medicine |
2014-08-31 |
| NCT01696461 |
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor |
https://ClinicalTrials.gov/show/NCT01696461 |
Completed |
Center for International Blood and Marrow Transplant Research |
2016-08-31 |
| NCT01678443 |
Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies |
https://ClinicalTrials.gov/show/NCT01678443 |
Active, not recruiting |
Fred Hutchinson Cancer Research Center |
2011-04-11 |
| NCT01665768 |
Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma |
https://ClinicalTrials.gov/show/NCT01665768 |
Active, not recruiting |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2017-10-31 |
| NCT01658319 |
Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01658319 |
Completed |
Case Comprehensive Cancer Center |
2015-02-28 |
| NCT01657331 |
Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL) |
https://ClinicalTrials.gov/show/NCT01657331 |
Active, not recruiting |
Columbia University |
2019-12-31 |
| NCT01619761 |
NK Cells in Cord Blood Transplantation |
https://ClinicalTrials.gov/show/NCT01619761 |
Active, not recruiting |
M.D. Anderson Cancer Center |
2021-11-30 |
| NCT01611298 |
Donor-Derived Humoral Immunity, Hematopoietic Stem Cell Transplantation, TAR |
https://ClinicalTrials.gov/show/NCT01611298 |
Completed |
Baylor College of Medicine |
2012-11-30 |
| NCT01588015 |
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT01588015 |
Active, not recruiting |
City of Hope Medical Center |
2021-11-30 |
| NCT01578967 |
Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01578967 |
Active, not recruiting |
UNC Lineberger Comprehensive Cancer Center |
2016-08-10 |
| NCT01572662 |
Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning |
https://ClinicalTrials.gov/show/NCT01572662 |
Active, not recruiting |
M.D. Anderson Cancer Center |
2020-04-30 |
| NCT01572519 |
A Study of JNJ-40346527 in Patients With Relapsed or Refractory Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01572519 |
Completed |
Janssen Research & Development, LLC |
2013-08-13 |
| NCT01569204 |
Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01569204 |
Completed |
University of Cologne |
2014-03-31 |
| NCT01567709 |
Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01567709 |
Completed |
National Cancer Institute (NCI) |
2018-03-29 |
| NCT01555892 |
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE |
https://ClinicalTrials.gov/show/NCT01555892 |
Recruiting |
Baylor College of Medicine |
2020-12-31 |
| NCT01535924 |
Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT01535924 |
Completed |
Ohio State University Comprehensive Cancer Center |
2019-02-20 |
| NCT01534078 |
Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01534078 |
Completed |
Massachusetts General Hospital |
2015-01-31 |
| NCT01529827 |
Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01529827 |
Completed |
Roswell Park Cancer Institute |
2015-05-28 |
| NCT01523847 |
A Multi-centre Study of MBVD in Elderly and/or Cardiopathic Patients Affected by Hodgkin’s Lymphoma (HL) |
https://ClinicalTrials.gov/show/NCT01523847 |
Completed |
Fondazione Italiana Linfomi ONLUS |
2013-10-31 |
| NCT01523223 |
Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies |
https://ClinicalTrials.gov/show/NCT01523223 |
Completed |
Stanford University |
2016-09-30 |
| NCT01508312 |
Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01508312 |
Active, not recruiting |
Memorial Sloan Kettering Cancer Center |
2021-09-30 |
| NCT01499147 |
Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01499147 |
Completed |
University of Illinois at Chicago |
2013-05-31 |
| NCT01492088 |
Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01492088 |
Completed |
Takeda |
2016-10-12 |
| NCT01487031 |
Music Therapy on Nausea and Pain for Autologous Stem Cell |
https://ClinicalTrials.gov/show/NCT01487031 |
Completed |
Case Comprehensive Cancer Center |
2013-04-30 |
| NCT01484015 |
Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia |
https://ClinicalTrials.gov/show/NCT01484015 |
Completed |
Wake Forest University Health Sciences |
2012-06-30 |
| NCT01476410 |
Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01476410 |
Active, not recruiting |
Northwestern University |
2021-05-31 |
| NCT01468311 |
Yttrium-90-labeled Daclizumab With Chemotherapy and Stem Cell Transplant for Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT01468311 |
Active, not recruiting |
National Institutes of Health Clinical Center (CC) |
2014-11-16 |
| NCT01460940 |
A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT01460940 |
Completed |
Ohio State University Comprehensive Cancer Center |
2016-11-16 |
| NCT01458288 |
A Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or in Combination With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease |
https://ClinicalTrials.gov/show/NCT01458288 |
Completed |
TaiGen Biotechnology Co., Ltd. |
2013-07-31 |
| NCT01453504 |
Everolimus in Combination With DHAP in Patients With Relapsed or Refractory Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01453504 |
Completed |
University of Cologne |
2019-03-31 |
| NCT01447056 |
Most Closely HLA-Matched CTLs for Relapsed Epstein Barr Virus(EBV)-Associated Diseases |
https://ClinicalTrials.gov/show/NCT01447056 |
Completed |
Baylor College of Medicine |
2015-03-31 |
| NCT01427881 |
Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT01427881 |
Completed |
Fred Hutchinson Cancer Research Center |
2014-06-30 |
| NCT01404936 |
Study of a-Interferon With Adriamycin, Bleomycin, Velban, and Dacarbazine (ABVD) With Hodgkin’s Disease |
https://ClinicalTrials.gov/show/NCT01404936 |
Completed |
M.D. Anderson Cancer Center |
2011-12-31 |
| NCT01393717 |
Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01393717 |
Completed |
City of Hope Medical Center |
2017-02-01 |
| NCT01393106 |
Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01393106 |
Completed |
Gilead Sciences |
2014-08-31 |
| NCT01384513 |
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT01384513 |
Recruiting |
Thomas Jefferson University |
2020-12-31 |
| NCT01358747 |
Study of a Treatment Driven by Early PET Response to a Treatment Not Monitored by Early PET in Patients With AA Stage 3-4 or 2B HL |
https://ClinicalTrials.gov/show/NCT01358747 |
Completed |
Centre Hospitalier Universitaire Dijon |
NA |
| NCT01356680 |
HD17 for Intermediate Stage Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01356680 |
Completed |
University of Cologne |
2020-03-21 |
| NCT01350245 |
Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor |
https://ClinicalTrials.gov/show/NCT01350245 |
Completed |
Thomas Jefferson University |
2013-05-31 |
| NCT01336712 |
Total Body Irradiation/Fludarabine Based Ablative Haploidentical Transplant for Hematologic Diseases |
https://ClinicalTrials.gov/show/NCT01336712 |
Completed |
Northside Hospital, Inc. |
2014-12-31 |
| NCT01333046 |
Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL |
https://ClinicalTrials.gov/show/NCT01333046 |
Recruiting |
Baylor College of Medicine |
2021-01-31 |
| NCT01326702 |
Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors |
https://ClinicalTrials.gov/show/NCT01326702 |
Completed |
National Cancer Institute (NCI) |
2015-04-30 |
| NCT01321346 |
A Study Of Panobinostat In Children With Refractory Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01321346 |
Completed |
Therapeutic Advances in Childhood Leukemia Consortium |
2015-10-31 |
| NCT04292626 |
Molecular Imaging of Lymphoma Using Labeled Technetium-99m 1-Thio-D-Glucose |
https://ClinicalTrials.gov/show/NCT04292626 |
Enrolling by invitation |
Tomsk National Research Medical Center of the Russian Academy of Sciences |
2021-02-19 |
| NCT04270266 |
Mind-Body Medicine for the Improvement of Quality of Life in Adolescents and Young Adults Coping With Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT04270266 |
Recruiting |
M.D. Anderson Cancer Center |
2021-06-30 |
| NCT04239170 |
Camrelizumab(SHR-1210) Combined With GEMOX in Patients With Relapsed or Refractory Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT04239170 |
Recruiting |
Peking University |
2022-12-31 |
| NCT04233294 |
Chidamide in Combination With Camrelizumab Alone or Plus Decitabine in Relapsed/Refractory Classical Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT04233294 |
Recruiting |
Chinese PLA General Hospital |
2024-02-29 |
| NCT04134325 |
Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT04134325 |
Recruiting |
UNC Lineberger Comprehensive Cancer Center |
2021-12-01 |
| NCT04090268 |
Precision Exercise in Children With Malignant Hemopathies |
https://ClinicalTrials.gov/show/NCT04090268 |
Recruiting |
University of Milano Bicocca |
2021-04-03 |
| NCT04067037 |
Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT04067037 |
Recruiting |
Henan Cancer Hospital |
2022-06-30 |
| NCT04052997 |
Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT04052997 |
Active, not recruiting |
ADC Therapeutics S.A. |
2021-11-30 |
| NCT04044222 |
A Study to Evaluate the Efficacy and Safety of the Sintilimab Plus ICE Regimen Versus ICE Regimen in the Classic Hodgkin’s Lymphoma Patients (cHL) Who Have Failed the First-line Standard Chemotherapy |
https://ClinicalTrials.gov/show/NCT04044222 |
Recruiting |
Innovent Biologics (Suzhou) Co. Ltd. |
2023-07-30 |
| NCT04026269 |
Clinical Efficacy of MOAP Regimen for Relapsed/Refractory cHL as a Rescue Therapy After DP Regimen |
https://ClinicalTrials.gov/show/NCT04026269 |
Recruiting |
Chinese PLA General Hospital |
2020-12-31 |
| NCT03968250 |
CBT on Fatigue in Survivors of Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT03968250 |
Active, not recruiting |
University of Leipzig |
2020-08-20 |
| NCT03935282 |
Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors |
https://ClinicalTrials.gov/show/NCT03935282 |
Enrolling by invitation |
Wake Forest University Health Sciences |
2023-05-31 |
| NCT03921879 |
Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma |
https://ClinicalTrials.gov/show/NCT03921879 |
Recruiting |
Oncotartis, Inc. |
2021-04-30 |
| NCT03776864 |
Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT03776864 |
Recruiting |
University of Washington |
2022-11-01 |
| NCT03755804 |
Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17 |
https://ClinicalTrials.gov/show/NCT03755804 |
Recruiting |
St. Jude Children’s Research Hospital |
2027-01-01 |
| NCT03739619 |
Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT03739619 |
Recruiting |
Emory University |
2022-11-30 |
| NCT03739502 |
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT03739502 |
Recruiting |
University of Rochester |
2021-04-30 |
| NCT03722147 |
A Study of Anti-PD-1 AK105 in Patients With Relapsed or Refractory Classic Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT03722147 |
Recruiting |
Akeso |
2020-03-01 |
| NCT03712202 |
Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT03712202 |
Recruiting |
City of Hope Medical Center |
2020-08-23 |
| NCT03681561 |
Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT03681561 |
Recruiting |
Big Ten Cancer Research Consortium |
2020-09-30 |
| NCT03655483 |
Study of GLS-010 Injection in the Treatment of Classical Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT03655483 |
Active, not recruiting |
Guangzhou Gloria Biosciences Co., Ltd. |
2021-04-11 |
| NCT03617666 |
Avelumab in the Frontline Treatment of Advanced Classical Hodgkin Lymphoma - a Window Study |
https://ClinicalTrials.gov/show/NCT03617666 |
Recruiting |
University College, London |
2020-10-31 |
| NCT03615664 |
The Efficacy of Bendamustine, Gemcytabine, Dexamethasone (BGD) Salvage Chemotherapy With Autologous Stem Cell Transplantation (ASCT) Consolidation in Advanced Classical Hodgkin Lymphoma Patients Not Responding to ABVD Therapy |
https://ClinicalTrials.gov/show/NCT03615664 |
Recruiting |
Polish Lymphoma Research Group |
2021-05-06 |
| NCT03598608 |
Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003) |
https://ClinicalTrials.gov/show/NCT03598608 |
Recruiting |
Merck Sharp & Dohme Corp. |
2025-11-05 |
| NCT03580408 |
Study Of Nivolumab Alone, Or In Combination With Vinblastin In Patients With Classical Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT03580408 |
Recruiting |
The Lymphoma Academic Research Organisation |
2020-12-31 |
| NCT03540849 |
BV After Allogeneic Hematopoietic Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT03540849 |
Recruiting |
University Hospital, Caen |
2020-03-07 |
| NCT03527628 |
OPTmizing Advanced Stage HodgkIn LymphoMa patIentS Therapy |
https://ClinicalTrials.gov/show/NCT03527628 |
Recruiting |
King Abdullah International Medical Research Center |
2021-01-15 |
| NCT03524235 |
Haploidentical Stem Cell Transplant With Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL |
https://ClinicalTrials.gov/show/NCT03524235 |
Recruiting |
Cedars-Sinai Medical Center |
2021-05-31 |
| NCT03517137 |
Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study |
https://ClinicalTrials.gov/show/NCT03517137 |
Recruiting |
European Organisation for Research and Treatment of Cancer - EORTC |
2021-03-01 |
| NCT03500133 |
Pediatric Hodgkin Lymphoma Treatment Trial With Low Cumulative Doses of Chemotherapy Agents and Reduced Radiation. |
https://ClinicalTrials.gov/show/NCT03500133 |
Recruiting |
Hospital JP Garrahan |
2027-10-31 |
| NCT03480334 |
Abscopal Effect of Radiotherapy and Nivolumab in Relapsed Hodgkin Lymphoma After Anti-PD1 Therapy |
https://ClinicalTrials.gov/show/NCT03480334 |
Recruiting |
University of Cologne |
2021-05-31 |
| NCT03436862 |
Nivolumab Maintenance Therapy After Autologous Stem Cell Transplant in Hodgkin Lymphoma Pts at Relapse/Progression Risk |
https://ClinicalTrials.gov/show/NCT03436862 |
Recruiting |
SCRI Development Innovations, LLC |
2021-09-30 |
| NCT01263899 |
A Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies |
https://ClinicalTrials.gov/show/NCT01263899 |
Completed |
S*BIO |
2012-02-29 |
| NCT01258998 |
Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma |
https://ClinicalTrials.gov/show/NCT01258998 |
Completed |
National Cancer Institute (NCI) |
2014-07-31 |
| NCT01251107 |
Study Comparing ABVD vs BEACOPP in Advanced Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT01251107 |
Completed |
Fondazione Michelangelo |
2009-11-30 |
| NCT01233921 |
Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT01233921 |
Completed |
Fred Hutchinson Cancer Research Center |
2012-07-31 |
| NCT01221571 |
A Study to Assess AFM13 in Patients With Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01221571 |
Completed |
Affimed GmbH |
2013-05-31 |
| NCT01207921 |
Lenalidomide Maintenance Therapy Post Autologous Transplant for Hodgkins Lymphoma |
https://ClinicalTrials.gov/show/NCT01207921 |
Active, not recruiting |
Washington University School of Medicine |
2016-09-19 |
| NCT01200329 |
High-Dose Gemcitabine, Busulfan and Melphalan for Patients With Refactory Hodgkin’s Disease |
https://ClinicalTrials.gov/show/NCT01200329 |
Completed |
M.D. Anderson Cancer Center |
2018-12-06 |
| NCT01195766 |
Study of Ofatumumab and ESHAP for the Treatment of Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT01195766 |
Completed |
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea |
2013-09-30 |
| NCT01192464 |
EBV CTLs Expressing CD30 Chimeric Receptors For CD 30+ Lymphoma |
https://ClinicalTrials.gov/show/NCT01192464 |
Active, not recruiting |
Baylor College of Medicine |
2012-05-29 |
| NCT01188798 |
Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01188798 |
Completed |
St. Jude Children’s Research Hospital |
2012-02-29 |
| NCT01187303 |
Ofatumumab in Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) |
https://ClinicalTrials.gov/show/NCT01187303 |
Completed |
University of Cologne |
2013-11-30 |
| NCT01181271 |
Tandem Auto-Allo Transplant for Lymphoma |
https://ClinicalTrials.gov/show/NCT01181271 |
Completed |
Massachusetts General Hospital |
2014-02-28 |
| NCT01177371 |
High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01177371 |
Completed |
Case Comprehensive Cancer Center |
2000-02-29 |
| NCT01221857 |
Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT01221857 |
Completed |
Gamida Cell ltd |
2012-09-30 |
| NCT01169636 |
Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01169636 |
Completed |
M.D. Anderson Cancer Center |
2017-05-17 |
| NCT01165112 |
Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma or Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01165112 |
Completed |
University of Washington |
2015-06-30 |
| NCT01164345 |
Mozobil for Autologous Stem Cell Mobilization |
https://ClinicalTrials.gov/show/NCT01164345 |
Completed |
Sheba Medical Center |
2015-05-31 |
| NCT01158274 |
RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors |
https://ClinicalTrials.gov/show/NCT01158274 |
Completed |
National Cancer Institute (NCI) |
2012-08-31 |
| NCT01158118 |
Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors |
https://ClinicalTrials.gov/show/NCT01158118 |
Completed |
Washington University School of Medicine |
2014-01-15 |
| NCT01149668 |
A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer |
https://ClinicalTrials.gov/show/NCT01149668 |
Completed |
Pharmacyclics LLC. |
2012-12-31 |
| NCT01132807 |
Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01132807 |
Completed |
Alliance for Clinical Trials in Oncology |
2016-02-29 |
| NCT01129193 |
AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma |
https://ClinicalTrials.gov/show/NCT01129193 |
Completed |
Ohio State University Comprehensive Cancer Center |
2017-01-07 |
| NCT01121120 |
Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients |
https://ClinicalTrials.gov/show/NCT01121120 |
Active, not recruiting |
Tarix Pharmaceuticals |
2020-06-30 |
| NCT01118026 |
Response-Based Therapy Assessed By PET Scan in Treating Patients With Bulky Stage I and Stage II Classical Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01118026 |
Active, not recruiting |
Alliance for Clinical Trials in Oncology |
2020-08-31 |
| NCT01110135 |
Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT01110135 |
Completed |
University of Washington |
2013-11-30 |
| NCT01088750 |
Surgery Alone, Surgery With Cyclophosphamide, Vinblastine, and Prednisolone (CVP), or CVP Alone in Treating Young Patients With Stage IA or Stage IIA Nodular Lymphocyte-Predominant Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01088750 |
Active, not recruiting |
Martin-Luther-Universität Halle-Wittenberg |
2023-10-31 |
| NCT01085058 |
Predictive Value of the “Cytocapacity Test” Patients With Lymphoproliferative Diseases and High-dose Therapy |
https://ClinicalTrials.gov/show/NCT01085058 |
Completed |
WiSP Wissenschaftlicher Service Pharma GmbH |
2004-12-31 |
| NCT01076543 |
Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01076543 |
Completed |
National Cancer Institute (NCI) |
2017-12-31 |
| NCT01060904 |
A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01060904 |
Completed |
Seattle Genetics, Inc. |
2012-09-30 |
| NCT01056679 |
Adriamycin, Vinblastine, DTIC and Revlimid in Elderly Hodgkin Lymphoma Patients |
https://ClinicalTrials.gov/show/NCT01056679 |
Completed |
University of Cologne |
2014-04-30 |
| NCT01053494 |
Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer |
https://ClinicalTrials.gov/show/NCT01053494 |
Completed |
Wake Forest University Health Sciences |
2012-02-29 |
| NCT01045382 |
MSC and HSC Coinfusion in Mismatched Minitransplants |
https://ClinicalTrials.gov/show/NCT01045382 |
Recruiting |
University of Liege |
2021-07-31 |
| NCT01037478 |
Resminostat (4SC-201) in Relapsed or Refractory Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT01037478 |
Completed |
4SC AG |
2012-01-31 |
| NCT01034163 |
A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin’s Lymphoma (HL) |
https://ClinicalTrials.gov/show/NCT01034163 |
Completed |
Novartis |
2012-05-31 |
| NCT01030900 |
Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas |
https://ClinicalTrials.gov/show/NCT01030900 |
Active, not recruiting |
National Institutes of Health Clinical Center (CC) |
2021-09-01 |
| NCT01026415 |
Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35) |
https://ClinicalTrials.gov/show/NCT01026415 |
Completed |
Seattle Genetics, Inc. |
2012-05-31 |
| NCT01026233 |
Cardiac Safety Study of Brentuximab Vedotin (SGN-35) |
https://ClinicalTrials.gov/show/NCT01026233 |
Completed |
Seattle Genetics, Inc. |
2010-08-31 |
| NCT01022996 |
Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment. |
https://ClinicalTrials.gov/show/NCT01022996 |
Completed |
Novartis |
2014-11-30 |
| NCT01018979 |
Safety and PK/PD of TG-0054 in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients |
https://ClinicalTrials.gov/show/NCT01018979 |
Completed |
TaiGen Biotechnology Co., Ltd. |
2011-10-31 |
| NCT01014507 |
Protection of Ovarian Function in Female Patients With Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01014507 |
Completed |
University of Cologne |
2009-09-30 |
| NCT01008462 |
Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia |
https://ClinicalTrials.gov/show/NCT01008462 |
Completed |
Fred Hutchinson Cancer Research Center |
2018-06-30 |
| NCT01004718 |
Detection and Quant of Differences in Hodgkin Lymphoma and Diffuse Large B-cell Lymphoma Using Positron Emission Tomography/Computed Tomography (PET/CT) |
https://ClinicalTrials.gov/show/NCT01004718 |
Completed |
Abramson Cancer Center of the University of Pennsylvania |
2013-07-31 |
| NCT00992030 |
R-ABVD vs ABVD-RT in Early Stage Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00992030 |
Active, not recruiting |
Fondazione Michelangelo |
2019-11-30 |
| NCT00990717 |
Safety Study Looking at the Use of a Natural Killer Cell Line Against Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT00990717 |
Completed |
University Health Network, Toronto |
2012-07-31 |
| NCT00990587 |
Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy |
https://ClinicalTrials.gov/show/NCT00990587 |
Completed |
University Health Network, Toronto |
2013-05-31 |
| NCT00982449 |
124I-FIAU Imaging in EBV and KSHV Associated Cancers |
https://ClinicalTrials.gov/show/NCT00982449 |
Completed |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2013-07-31 |
| NCT00975975 |
Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer |
https://ClinicalTrials.gov/show/NCT00975975 |
Completed |
Indiana University |
2012-10-31 |
| NCT00967369 |
Combination Chemotherapy With or Without Bortezomib in Treating Patients With Classical Hodgkin Lymphoma That Has Returned or Does Not Respond to Prior Treatment. |
https://ClinicalTrials.gov/show/NCT00967369 |
Completed |
M.D. Anderson Cancer Center |
2018-05-02 |
| NCT00952237 |
Immune Mobilization of Autologous Peripheral Blood Stem Cells Using Interleukin-2 and GM-CSF |
https://ClinicalTrials.gov/show/NCT00952237 |
Completed |
Dartmouth-Hitchcock Medical Center |
2011-04-30 |
| NCT00947856 |
A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study |
https://ClinicalTrials.gov/show/NCT00947856 |
Completed |
Seattle Genetics, Inc. |
2013-03-31 |
| NCT00918333 |
Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT00918333 |
Completed |
Mayo Clinic |
2015-12-01 |
| NCT00901225 |
Study of Plerixafor for Rescue of Poor Mobilizers in Autologous Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT00901225 |
Completed |
Duke University |
2010-08-31 |
| NCT00901069 |
Azacitidine With Rituximab, Vincristine, and Cyclophosphamide in Refractory Lymphoma |
https://ClinicalTrials.gov/show/NCT00901069 |
Completed |
University of Kentucky |
2012-01-31 |
| NCT00891592 |
Umbilical Cord Blood Transplant for Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT00891592 |
Completed |
University of Pennsylvania |
2011-11-30 |
| NCT00890747 |
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy |
https://ClinicalTrials.gov/show/NCT00890747 |
Completed |
National Cancer Institute (NCI) |
2011-05-31 |
| NCT00887718 |
Positron Emission Tomography(PET) in Lymphoma Assessment |
https://ClinicalTrials.gov/show/NCT00887718 |
Completed |
University Health Network, Toronto |
2011-06-30 |
| NCT00871702 |
Infusion of Genetically Modified T Cell for Post Transplant Patients With Relapsed Disease |
https://ClinicalTrials.gov/show/NCT00871702 |
Completed |
Washington University School of Medicine |
2012-11-30 |
| NCT00867529 |
Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00867529 |
Completed |
Fred Hutchinson Cancer Research Center |
2015-03-31 |
| NCT00856388 |
Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders |
https://ClinicalTrials.gov/show/NCT00856388 |
Completed |
Roswell Park Cancer Institute |
2012-08-09 |
| NCT00850200 |
Proton Therapy for Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT00850200 |
Completed |
University of Florida |
2013-05-31 |
| NCT00848926 |
A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT00848926 |
Completed |
Seattle Genetics, Inc. |
2010-08-31 |
| NCT00846742 |
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Favorable-Risk Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT00846742 |
Active, not recruiting |
St. Jude Children’s Research Hospital |
2019-01-11 |
| NCT02867618 |
Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma |
https://ClinicalTrials.gov/show/NCT02867618 |
Recruiting |
Columbia University |
2020-10-31 |
| NCT00822120 |
S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT00822120 |
Active, not recruiting |
Southwest Oncology Group |
2016-04-30 |
| NCT02593123 |
Allogeneic Stem Cell Transplantationin Relapsed Hematological Malignancy: Early GVHD Prophylaxis |
https://ClinicalTrials.gov/show/NCT02593123 |
Active, not recruiting |
Virginia Commonwealth University |
2025-12-31 |
| NCT01527838 |
Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit |
https://ClinicalTrials.gov/show/NCT01527838 |
Completed |
Fate Therapeutics |
2013-10-31 |
| NCT00838357 |
A Multi-centre, Open Label, Single-arm Study Intended to Further Investigate the Safety and Efficacy of Plerixafor as a Front-line Mobilisation Agent in Combination With G-CSF in Patients With Lymphoma or MM (Multiple Myeloma). |
https://ClinicalTrials.gov/show/NCT00838357 |
Completed |
Sanofi |
2010-11-30 |
| NCT01758042 |
Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders |
https://ClinicalTrials.gov/show/NCT01758042 |
Recruiting |
Massachusetts General Hospital |
2019-07-31 |
| NCT01413568 |
Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01413568 |
Completed |
Polyphor Ltd. |
2015-11-30 |
| NCT03878524 |
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial |
https://ClinicalTrials.gov/show/NCT03878524 |
Recruiting |
OHSU Knight Cancer Institute |
2022-02-27 |
| NCT00802113 |
Autologous and Allogeneic Transplant for Relapsed Lymphoma |
https://ClinicalTrials.gov/show/NCT00802113 |
Completed |
Columbia University |
2014-10-31 |
| NCT01217229 |
Safety and Efficacy Study of PLX3397 in Adults With Relapsed or Refractory Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01217229 |
Completed |
Daiichi Sankyo, Inc. |
2012-04-26 |
| NCT03618550 |
Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT03618550 |
Recruiting |
Memorial Sloan Kettering Cancer Center |
2021-08-31 |
| NCT02927769 |
A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin’s Lymphoma (cHL), Relapsed or Refractory From First Line Treatment |
https://ClinicalTrials.gov/show/NCT02927769 |
Recruiting |
Bristol-Myers Squibb |
2023-03-27 |
| NCT03576378 |
BrEPEM-LH-22017 for Older Patients With Untreated Hodgkin Lymphoma (HL) |
https://ClinicalTrials.gov/show/NCT03576378 |
Recruiting |
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea |
2023-10-30 |
| NCT01780662 |
Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01780662 |
Active, not recruiting |
National Cancer Institute (NCI) |
2017-09-30 |
| NCT01701986 |
Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01701986 |
Recruiting |
M.D. Anderson Cancer Center |
2020-05-01 |
| NCT01476839 |
Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01476839 |
Active, not recruiting |
City of Hope Medical Center |
2021-01-31 |
| NCT03697408 |
Itacitinib + Everolimus in Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT03697408 |
Recruiting |
University of Pennsylvania |
2026-01-31 |
| NCT03505996 |
A Study of CS1001 in Subjects With Relapsed or Refractory Classical Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT03505996 |
Recruiting |
CStone Pharmaceuticals |
2019-12-31 |
| NCT03474133 |
Brentuximab Vedotin as Alternative to the Autologous Stem Cell Transplantation in Relapsed and Refractory Classical Hodgkin’s Lymphoma (BASALT) |
https://ClinicalTrials.gov/show/NCT03474133 |
Recruiting |
Federal Research Institute of Pediatric Hematology, Oncology and Immunology |
2023-10-01 |
| NCT01231919 |
MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia |
https://ClinicalTrials.gov/show/NCT01231919 |
Completed |
National Cancer Institute (NCI) |
2013-04-30 |
| NCT00792467 |
Phase II Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin’s Lymphoma Patients |
https://ClinicalTrials.gov/show/NCT00792467 |
Completed |
Italfarmaco |
2010-07-31 |
| NCT00784537 |
High-dose Chemotherapy and Stem Cell Transplantation, in Patients PET-2 Positive, After 2 Courses of ABVD and Comparison of RT Versus no RT in PET-2 Negative Patients |
https://ClinicalTrials.gov/show/NCT00784537 |
Completed |
Fondazione Italiana Linfomi ONLUS |
2015-01-31 |
| NCT00779584 |
A Dose-escalation Study of MK-8776 (SCH 900776) With and Without Gemcitabine in Participants With Solid Tumors or Lymphoma (MK-8776-002/P05248) |
https://ClinicalTrials.gov/show/NCT00779584 |
Completed |
Merck Sharp & Dohme Corp. |
2011-05-28 |
| NCT00769288 |
FAU in Treating Patients With Advanced Solid Tumors or Lymphoma |
https://ClinicalTrials.gov/show/NCT00769288 |
Completed |
National Cancer Institute (NCI) |
2013-12-31 |
| NCT00754286 |
A Randomized Trial of The Effectiveness of Aromatherapy on Chemotherapy Induced Nausea and Vomiting in Children With Cancer |
https://ClinicalTrials.gov/show/NCT00754286 |
Completed |
Albert Einstein College of Medicine |
2011-07-31 |
| NCT00742027 |
Phase II Study of Oral Panobinostat in Adult Patients With Relapsed/Refractory Classical Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00742027 |
Completed |
Novartis |
2013-08-31 |
| NCT00741871 |
A Phase 1 Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies |
https://ClinicalTrials.gov/show/NCT00741871 |
Completed |
S*BIO |
2011-10-31 |
| NCT00736320 |
HD16 for Early Stage Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT00736320 |
Active, not recruiting |
University of Cologne |
2018-09-30 |
| NCT00733824 |
Intravenous AMD3100 for Collection of Autologous Peripheral Blood Stem Cells in Patients With Lymphoma |
https://ClinicalTrials.gov/show/NCT00733824 |
Completed |
Washington University School of Medicine |
2012-09-30 |
| NCT00724984 |
Study of the Safety and Tolerability of PCI-24781 in Patients With Lymphoma |
https://ClinicalTrials.gov/show/NCT00724984 |
Completed |
Pharmacyclics LLC. |
2012-11-30 |
| NCT00718757 |
Irinotecan, Vincristine, and Dexamethasone In Children With Relapsed And/Or Refractory Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00718757 |
Completed |
St. Jude Children’s Research Hospital |
2009-01-31 |
| NCT00705250 |
Bendamustine HCL in Relapsed and Primary Refractory Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT00705250 |
Completed |
Memorial Sloan Kettering Cancer Center |
2015-12-31 |
| NCT00697684 |
Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT00697684 |
Active, not recruiting |
Dana-Farber Cancer Institute |
2020-12-31 |
| NCT00691210 |
Phase I Vorinostat in Combination With Niacinamide and Etoposide for Lymphoid Malignancies |
https://ClinicalTrials.gov/show/NCT00691210 |
Completed |
Columbia University |
2014-02-28 |
| NCT00683046 |
T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00683046 |
Completed |
University of Chicago |
2014-12-31 |
| NCT00678327 |
Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT00678327 |
Active, not recruiting |
University College, London |
2016-01-31 |
| NCT00670592 |
Study of HCD122 in Adults With Non-Hodgkin’s or Hodgkin’s Lymphoma Who Have Progressed After at Least Two Prior Therapies |
https://ClinicalTrials.gov/show/NCT00670592 |
Completed |
Novartis |
2013-02-28 |
| NCT00667615 |
Trial of Vorinostat in Combination With Cyclophosphamide, Etoposide, Prednisone and Rituximab for Elderly Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) |
https://ClinicalTrials.gov/show/NCT00667615 |
Completed |
Memorial Sloan Kettering Cancer Center |
2017-02-28 |
| NCT00666484 |
Combination Chemotherapy in Treating Younger Patients With Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT00666484 |
Completed |
University College, London |
2012-09-30 |
| NCT00665314 |
Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM). |
https://ClinicalTrials.gov/show/NCT00665314 |
Completed |
Sanofi |
2008-04-30 |
| NCT00654732 |
Combination Chemotherapy With or Without Rituximab in Treating Participants With Stage III-IV Classic Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT00654732 |
Completed |
M.D. Anderson Cancer Center |
2018-09-05 |
| NCT00652626 |
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function |
https://ClinicalTrials.gov/show/NCT00652626 |
Completed |
Celgene |
2012-07-01 |
| NCT00648037 |
Rituximab (Rituxan) for the Prevention of EBV-LPD Epstein Barr Virus (EBV) Lymphoproliferative Disorder Post T Cell Depleted Unrelated and HLA Mis-matched Related HSCT |
https://ClinicalTrials.gov/show/NCT00648037 |
Completed |
Memorial Sloan Kettering Cancer Center |
2008-12-31 |
| NCT00636909 |
Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders |
https://ClinicalTrials.gov/show/NCT00636909 |
Completed |
Beth Israel Deaconess Medical Center |
2006-03-31 |
| NCT00636311 |
A Phase II Study of IGEV +/- Bortezomib Before Hign Dose Consolidation in Relapsed/Refractory Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00636311 |
Completed |
Istituto Clinico Humanitas |
2008-04-30 |
| NCT00634452 |
Phase 1 Study of MDX-1401 in Patients With CD30-positive Refractory/Relapsed Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00634452 |
Completed |
Bristol-Myers Squibb |
2010-01-31 |
| NCT00608361 |
Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery |
https://ClinicalTrials.gov/show/NCT00608361 |
Completed |
National Cancer Institute (NCI) |
2014-08-31 |
| NCT00606645 |
Safety Study of XmAb®2513 to Treat Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00606645 |
Completed |
Xencor, Inc. |
2010-04-30 |
| NCT00606437 |
Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants |
https://ClinicalTrials.gov/show/NCT00606437 |
Completed |
Duke University |
2014-02-28 |
| NCT00601718 |
Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00601718 |
Completed |
University of Washington |
2010-06-30 |
| NCT00601146 |
Low-Dose Chest Computed Tomography Screening for Lung Cancer in Survivors of Hodgkin’s Disease |
https://ClinicalTrials.gov/show/NCT00601146 |
Completed |
Dana-Farber Cancer Institute |
2010-12-01 |
| NCT00597714 |
Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT00597714 |
Completed |
Duke University |
2013-07-31 |
| NCT00592111 |
A Comprehensive Study of Clinically Staged Pediatric Hodgkin’s Disease: Chemotherapy for All Patients; Supplementary Low Dose Involved Field Irradiation for Selected Patients (CCG 5942) |
https://ClinicalTrials.gov/show/NCT00592111 |
Completed |
Memorial Sloan Kettering Cancer Center |
1999-02-28 |
| NCT00587873 |
Sequential Administration of Oral 6-Thioguanine (6-TG) After Methotrexate (MTX) in Patients With Relapsed Hodgkin’s Disease (Phase II) |
https://ClinicalTrials.gov/show/NCT00587873 |
Completed |
Memorial Sloan Kettering Cancer Center |
2003-12-31 |
| NCT00581815 |
Spectroscopy With Surface Coils and Decoupling |
https://ClinicalTrials.gov/show/NCT00581815 |
Completed |
Memorial Sloan Kettering Cancer Center |
2014-02-28 |
| NCT00577798 |
Cardiac Magnetic Resonance Imaging in Patients With Newly Diagnosed Non-Hodgkin Lymphoma or Hodgkin Lymphoma Receiving Doxorubicin |
https://ClinicalTrials.gov/show/NCT00577798 |
Completed |
University of Nebraska |
2012-12-31 |
| NCT00574496 |
Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT00574496 |
Active, not recruiting |
Memorial Sloan Kettering Cancer Center |
2021-11-30 |
| NCT00571662 |
Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT00571662 |
Completed |
University of Nebraska |
2008-12-31 |
| NCT00562224 |
Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer Patients |
https://ClinicalTrials.gov/show/NCT00562224 |
Completed |
Pharmacyclics LLC. |
2010-06-30 |
| NCT00551798 |
Prediction of the Response to Chemotherapy by Tomoscintigraphie the MIBI in the Balance Sheet Pre Hodgkin’s Disease and Lymphoma Malins High Grade |
https://ClinicalTrials.gov/show/NCT00551798 |
Completed |
University Hospital, Limoges |
2011-01-31 |
| NCT00540007 |
Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT00540007 |
Completed |
Washington University School of Medicine |
2016-09-01 |
| NCT00539695 |
Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD |
https://ClinicalTrials.gov/show/NCT00539695 |
Completed |
Baylor College of Medicine |
2013-04-30 |
| NCT00536601 |
High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors |
https://ClinicalTrials.gov/show/NCT00536601 |
Completed |
Roswell Park Cancer Institute |
2018-07-09 |
| NCT00534989 |
Use of FDG PET as Predictor of Residual Disease and Subsequent Relapse in Patients With NHL and HD Undergoing HDC and ASCT |
https://ClinicalTrials.gov/show/NCT00534989 |
Completed |
King Faisal Specialist Hospital & Research Center |
2013-02-28 |
| NCT00534820 |
Cytogenetic Analysis of Bone Marrow Specimen Prior to High Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Non-Hodgkin’s Lymphoma or Hodgkin’s Disease |
https://ClinicalTrials.gov/show/NCT00534820 |
Completed |
King Faisal Specialist Hospital & Research Center |
2013-08-31 |
| NCT00533923 |
Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders |
https://ClinicalTrials.gov/show/NCT00533923 |
Completed |
Beth Israel Deaconess Medical Center |
2007-01-31 |
| NCT00516217 |
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00516217 |
Completed |
Alliance for Clinical Trials in Oncology |
2011-09-30 |
| NCT00515554 |
HD18 for Advanced Stages in Hodgkins Lymphoma |
https://ClinicalTrials.gov/show/NCT00515554 |
Active, not recruiting |
University of Cologne |
2020-06-30 |
| NCT00504504 |
Rituximab and ABVD for Hodgkin’s Patients |
https://ClinicalTrials.gov/show/NCT00504504 |
Completed |
M.D. Anderson Cancer Center |
2012-03-31 |
| NCT00499811 |
Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction |
https://ClinicalTrials.gov/show/NCT00499811 |
Completed |
National Cancer Institute (NCI) |
2011-08-31 |
| NCT00489203 |
Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00489203 |
Completed |
Fred Hutchinson Cancer Research Center |
2010-11-30 |
| NCT00484874 |
Safety and Efficacy Study of I-131 Tositumomab in Patients With Relapsed/Refractory Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00484874 |
Completed |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2014-01-31 |
| NCT00481871 |
Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies |
https://ClinicalTrials.gov/show/NCT00481871 |
Completed |
Acrotech Biopharma LLC |
2011-05-31 |
| NCT00478959 |
Phase II Study of Lenalidomide for the Treatment of Relapsed or Refractory Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00478959 |
Completed |
University Health Network, Toronto |
2014-06-30 |
| NCT00469729 |
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy |
https://ClinicalTrials.gov/show/NCT00469729 |
Completed |
Gamida Cell -Teva Joint Venture Ltd. |
2013-02-28 |
| NCT00460694 |
Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies |
https://ClinicalTrials.gov/show/NCT00460694 |
Completed |
Singapore General Hospital |
2012-12-31 |
| NCT00458731 |
Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma |
https://ClinicalTrials.gov/show/NCT00458731 |
Completed |
National Cancer Institute (NCI) |
2013-12-31 |
| NCT00444912 |
The Effect of Rituximab on Mobilization With AMD3100 (Plerixafor) Plus G-CSF in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) or Hodgkin Disease (HD) |
https://ClinicalTrials.gov/show/NCT00444912 |
Completed |
Sanofi |
2009-06-30 |
| NCT00443677 |
Treatment of Advanced Hodgkin’s Disease (Stages IIB-III-IV) |
https://ClinicalTrials.gov/show/NCT00443677 |
Completed |
Gruppo Italiano Studio Linfomi |
NA |
| NCT00439361 |
Velcade Plus ICE for Patients With Relapsed Classical Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT00439361 |
Completed |
M.D. Anderson Cancer Center |
2012-06-30 |
| NCT00433459 |
Combination Chemotherapy in Treating Young Patients With Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00433459 |
Completed |
Martin-Luther-Universität Halle-Wittenberg |
2013-01-31 |
| NCT00433433 |
Fludeoxyglucose F 18 PET Scan-Guided Therapy or Standard Therapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00433433 |
Completed |
European Organisation for Research and Treatment of Cancer - EORTC |
2011-12-31 |
| NCT00430846 |
Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00430846 |
Completed |
Seattle Genetics, Inc. |
2009-07-31 |
| NCT01075321 |
Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01075321 |
Active, not recruiting |
Mayo Clinic |
2015-02-28 |
| NCT00423709 |
Allogeneic Blood Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT00423709 |
Completed |
M.D. Anderson Cancer Center |
2007-08-31 |
| NCT00416832 |
Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00416832 |
Completed |
Martin-Luther-Universität Halle-Wittenberg |
2005-12-31 |
| NCT00408681 |
Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT00408681 |
Completed |
Fred Hutchinson Cancer Research Center |
2010-11-30 |
| NCT00398554 |
Combination Chemotherapy in Treating Young Male Patients With Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00398554 |
Completed |
Martin-Luther-Universität Halle-Wittenberg |
2012-10-31 |
| NCT00398411 |
Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells |
https://ClinicalTrials.gov/show/NCT00398411 |
Completed |
University of Cologne |
2008-12-31 |
| NCT00396201 |
AMD3100 (Plerixafor) Added to a Mobilizing Regimen of Granulocyte-colony Stimulating Factor (G-CSF) to Increase the Number of Peripheral Blood Stem Cells (PBSCs) in Patients With Hodgkin’s Disease |
https://ClinicalTrials.gov/show/NCT00396201 |
Completed |
Sanofi |
2006-10-31 |
| NCT00392314 |
Tailored Therapy for Hodgkin Lymphoma Using Early Interim Therapy PET for Therapy Decision. |
https://ClinicalTrials.gov/show/NCT00392314 |
Completed |
Rambam Health Care Campus |
2014-05-31 |
| NCT00388349 |
Gemcitabine and Hodgkin’s Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin’s Disease |
https://ClinicalTrials.gov/show/NCT00388349 |
Completed |
Stanford University |
2008-03-31 |
| NCT00799461 |
Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications |
https://ClinicalTrials.gov/show/NCT00799461 |
Completed |
Fred Hutchinson Cancer Research Center |
2011-11-30 |
| NCT00385788 |
Allogeneic Blood Stem Cell Transplantation and Adoptive Immunotherapy for Hodgkin’s Disease |
https://ClinicalTrials.gov/show/NCT00385788 |
Completed |
M.D. Anderson Cancer Center |
2016-08-31 |
| NCT00381940 |
Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin’s Lymphoma That is Recurrent or Did Not Respond to Previous Therapy |
https://ClinicalTrials.gov/show/NCT00381940 |
Completed |
National Cancer Institute (NCI) |
2008-06-30 |
| NCT00369681 |
Phase 2 Study of Rituximab-ABVD in Classical Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT00369681 |
Completed |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2014-10-31 |
| NCT00368082 |
Autologous/Allogeneic TGFbeta-resistant LMP-specific CTL, Lymphoma (TGF-beta) |
https://ClinicalTrials.gov/show/NCT00368082 |
Active, not recruiting |
Baylor College of Medicine |
2013-09-30 |
| NCT00364676 |
Study of Vinorelbine Liposomes Injection for Advanced Solid Tumors, Non-Hodgkin’s Lymphoma or Hodgkin’s Disease |
https://ClinicalTrials.gov/show/NCT00364676 |
Completed |
Spectrum Pharmaceuticals, Inc |
2015-06-30 |
| NCT00359892 |
Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00359892 |
Completed |
Teva Pharmaceutical Industries |
2007-09-30 |
| NCT00352027 |
Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT00352027 |
Active, not recruiting |
St. Jude Children’s Research Hospital |
2015-05-31 |
| NCT00348985 |
PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas |
https://ClinicalTrials.gov/show/NCT00348985 |
Completed |
National Cancer Institute (NCI) |
2010-01-31 |
| NCT00346684 |
Rituximab in Primary Lymphocyte Predominant Hodgkin´s Disease(RIPL) |
https://ClinicalTrials.gov/show/NCT00346684 |
Completed |
University of Cologne |
2007-11-30 |
| NCT00343564 |
A Study of SB-743921 in Non-Hodgkin Lymphoma and Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT00343564 |
Completed |
Cytokinetics |
2010-07-31 |
| NCT00337194 |
SGN-30 and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT00337194 |
Completed |
National Cancer Institute (NCI) |
2008-09-30 |
| NCT00305149 |
Risk Adapted Beacopp Regimen for Standard and High Risk Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT00305149 |
Completed |
Rambam Health Care Campus |
NA |
| NCT00302003 |
Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00302003 |
Completed |
Children’s Oncology Group |
2012-03-31 |
| NCT00293345 |
3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma |
https://ClinicalTrials.gov/show/NCT00293345 |
Completed |
National Cancer Institute (NCI) |
2012-10-31 |
| NCT00285259 |
Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT) |
https://ClinicalTrials.gov/show/NCT00285259 |
Completed |
Astellas Pharma Inc |
2009-11-30 |
| NCT00284804 |
A Phase II Study of MDX-060 in Subjects With Relapsed or Refractory Hodgkin’s Disease |
https://ClinicalTrials.gov/show/NCT00284804 |
Completed |
Bristol-Myers Squibb |
2008-05-31 |
| NCT00284271 |
Feasibility and Efficacy of BACOPP-21 for Patients > 60 Years With Intermediate or Advanced Hodgkins Lymphoma |
https://ClinicalTrials.gov/show/NCT00284271 |
Completed |
University of Cologne |
2005-12-31 |
| NCT00283439 |
A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With Lymphoma |
https://ClinicalTrials.gov/show/NCT00283439 |
Completed |
Amgen |
2008-05-31 |
| NCT00265031 |
HD12 for Advanced Stages |
https://ClinicalTrials.gov/show/NCT00265031 |
Completed |
University of Cologne |
NA |
| NCT00265018 |
HD10 for Early Stages |
https://ClinicalTrials.gov/show/NCT00265018 |
Completed |
University of Cologne |
2003-01-31 |
| NCT00264953 |
HD11 for Intermediate Stages |
https://ClinicalTrials.gov/show/NCT00264953 |
Completed |
University of Cologne |
2003-01-31 |
| NCT00262860 |
Bortezomib and Gemcitabine Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00262860 |
Completed |
University of Rochester |
2008-05-31 |
| NCT00261677 |
A Study to Evaluate the Effect of Weekly PROCRIT (Epoetin Alfa) or Placebo on Anemia and Quality of Life in Children With Cancer Undergoing Chemotherapy |
https://ClinicalTrials.gov/show/NCT00261677 |
Completed |
Ortho Biotech Products, L.P. |
NA |
| NCT00256191 |
Study of TPI 287 Administered Every 21 Days in Patients With Advanced Malignancies |
https://ClinicalTrials.gov/show/NCT00256191 |
Completed |
Cortice Biosciences, Inc. |
NA |
| NCT00255723 |
Combination Chemotherapy and Radiation Therapy in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed or Refractory Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00255723 |
Completed |
Memorial Sloan Kettering Cancer Center |
2012-07-31 |
| NCT00241358 |
Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT00241358 |
Completed |
Washington University School of Medicine |
2009-12-31 |
| NCT00232440 |
Reproducibility of an Immobilization Device (BodyFIX) - Hodgkins/Lymphoma |
https://ClinicalTrials.gov/show/NCT00232440 |
Completed |
University Health Network, Toronto |
2009-06-30 |
| NCT00196885 |
Effect of an Antioxidant on Cancer-Cachectic Patients Undergoing Exercise Training |
https://ClinicalTrials.gov/show/NCT00196885 |
Completed |
German Cancer Research Center |
NA |
| NCT00186251 |
High Dose Chemotherapy Followed By PBSC Rescue for HD |
https://ClinicalTrials.gov/show/NCT00186251 |
Completed |
Stanford University |
NA |
| NCT00185692 |
Allogeneic Transplantation From Related Haploidentical Donors |
https://ClinicalTrials.gov/show/NCT00185692 |
Completed |
Stanford University |
2010-12-31 |
| NCT00165425 |
Cardiac Screening in Survivors of Hodgkin’s Disease Treated With Mediastinal Irradiation |
https://ClinicalTrials.gov/show/NCT00165425 |
Active, not recruiting |
Dana-Farber Cancer Institute |
2007-10-31 |
| NCT00165308 |
Tamoxifen in the Prevention of Breast Cancer in Hodgkin’s Disease Survivors |
https://ClinicalTrials.gov/show/NCT00165308 |
Completed |
Dana-Farber Cancer Institute |
2004-03-31 |
| NCT00145613 |
Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT00145613 |
Completed |
St. Jude Children’s Research Hospital |
2006-07-31 |
| NCT00163761 |
Efficacy Study of Outpatient Therapy for Lymphoma |
https://ClinicalTrials.gov/show/NCT00163761 |
Completed |
Bayside Health |
2008-02-29 |
| NCT00163748 |
Efficacy and Treatment Related Toxicity Study of a New Regimen for Lymphoma |
https://ClinicalTrials.gov/show/NCT00163748 |
Completed |
Bayside Health |
2003-11-30 |
| NCT00150462 |
Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT00150462 |
Completed |
Amgen |
2009-10-31 |
| NCT00147875 |
Study of Prednisone, Vinblastine, Doxorubicin, and Gemcitabine in Elderly Patients With Advanced Stages Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00147875 |
Completed |
University of Cologne |
2007-07-31 |
| NCT00145600 |
Therapy for Pediatric Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT00145600 |
Active, not recruiting |
St. Jude Children’s Research Hospital |
2012-05-31 |
| NCT00144703 |
Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT00144703 |
Completed |
Dana-Farber Cancer Institute |
2006-11-30 |
| NCT00144677 |
Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT00144677 |
Completed |
Dana-Farber Cancer Institute |
2006-06-30 |
| NCT00136474 |
Amifostine for Head and Neck Irradiation in Lymphoma |
https://ClinicalTrials.gov/show/NCT00136474 |
Completed |
Dana-Farber Cancer Institute |
2005-05-31 |
| NCT00134082 |
Rituximab and Cyclophosphamide Followed by Vaccine Therapy in Treating Patients With Relapsed Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT00134082 |
Completed |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2013-01-31 |
| NCT00133367 |
Study of Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus |
https://ClinicalTrials.gov/show/NCT00133367 |
Completed |
Massachusetts General Hospital |
2007-11-30 |
| NCT00132028 |
Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00132028 |
Completed |
National Cancer Institute (NCI) |
2009-05-31 |
| NCT00118352 |
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00118352 |
Completed |
Fred Hutchinson Cancer Research Center |
2010-07-31 |
| NCT00117988 |
17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00117988 |
Completed |
National Cancer Institute (NCI) |
2010-04-30 |
| NCT00113724 |
Study of TPI 287 in Patients With Advanced Malignancies |
https://ClinicalTrials.gov/show/NCT00113724 |
Completed |
Cortice Biosciences, Inc. |
2008-01-31 |
| NCT00112593 |
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer |
https://ClinicalTrials.gov/show/NCT00112593 |
Completed |
Fred Hutchinson Cancer Research Center |
2014-11-30 |
| NCT00105001 |
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00105001 |
Completed |
Fred Hutchinson Cancer Research Center |
2011-05-31 |
| NCT00098891 |
MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas |
https://ClinicalTrials.gov/show/NCT00098891 |
Completed |
National Cancer Institute (NCI) |
2008-03-31 |
| NCT00090909 |
Gemcitabine, Cisplatin, and Dexamethasone in Treating Patients With Relapsed or Refractory Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00090909 |
Completed |
Jonsson Comprehensive Cancer Center |
2005-03-31 |
| NCT00089271 |
17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas |
https://ClinicalTrials.gov/show/NCT00089271 |
Completed |
National Cancer Institute (NCI) |
2010-06-30 |
| NCT00089011 |
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00089011 |
Completed |
Fred Hutchinson Cancer Research Center |
2014-03-31 |
| NCT00004169 |
Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hodgkin’s Disease |
https://ClinicalTrials.gov/show/NCT00004169 |
Completed |
Northwestern University |
2007-01-31 |
| NCT00003936 |
Bryostatin 1 in Treating Patients With Recurrent or Refractory Hodgkin’s Disease |
https://ClinicalTrials.gov/show/NCT00003936 |
Completed |
Barbara Ann Karmanos Cancer Institute |
2004-06-30 |
| NCT00002495 |
SWOG-9133 RT w/ or w/o Doxorubicin and Vinblastine in Stage I or Stage II Hodgkin’s Disease |
https://ClinicalTrials.gov/show/NCT00002495 |
Completed |
Southwest Oncology Group |
2000-11-30 |
| NCT00086801 |
Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00086801 |
Completed |
Alliance for Clinical Trials in Oncology |
2007-03-31 |
| NCT00006251 |
Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer |
https://ClinicalTrials.gov/show/NCT00006251 |
Completed |
Fred Hutchinson Cancer Research Center |
2005-09-30 |
| NCT00005578 |
Combination Chemotherapy With or Without Dexrazoxane in Treating Children With Hodgkin’s Disease |
https://ClinicalTrials.gov/show/NCT00005578 |
Completed |
Children’s Oncology Group |
2004-10-31 |
| NCT00002827 |
Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin’s Disease |
https://ClinicalTrials.gov/show/NCT00002827 |
Completed |
Children’s Oncology Group |
2004-10-31 |
| NCT00002552 |
Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Refractory Non-Hodgkin’s Lymphoma, Hodgkin’s Disease, or Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT00002552 |
Completed |
Barbara Ann Karmanos Cancer Institute |
2001-09-30 |
| NCT00082888 |
Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma |
https://ClinicalTrials.gov/show/NCT00082888 |
Completed |
National Cancer Institute (NCI) |
2009-05-20 |
| NCT00082966 |
Bortezomib in Treating Patients With Relapsed or Refractory Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00082966 |
Completed |
National Cancer Institute (NCI) |
2007-03-31 |
| NCT00003849 |
Rituximab in Treating Patients With Non-Hodgkin’s Lymphoma or Hodgkin’s Disease |
https://ClinicalTrials.gov/show/NCT00003849 |
Completed |
Alliance for Clinical Trials in Oncology |
2005-02-28 |
| NCT00002745 |
Aminocamptothecin in Treating Patients With Refractory or Recurrent Hodgkin’s Disease or Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00002745 |
Completed |
National Cancer Institute (NCI) |
2003-04-30 |
| NCT00004010 |
Combination Chemotherapy and Radiation Therapy in Treating Children With Previously Untreated Stage II, Stage III, or Stage IV Hodgkin’s Disease |
https://ClinicalTrials.gov/show/NCT00004010 |
Completed |
Children’s Oncology Group |
2003-10-31 |
| NCT00002714 |
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Early-Stage Hodgkin’s Disease |
https://ClinicalTrials.gov/show/NCT00002714 |
Completed |
National Cancer Institute (NCI) |
NA |
| NCT00002461 |
Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Refractory Hodgkin’s Disease or Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00002461 |
Completed |
Montefiore Medical Center |
1991-07-31 |
| NCT00003421 |
Combination Chemotherapy in Treating Patients With Advanced Hodgkin’s Disease |
https://ClinicalTrials.gov/show/NCT00003421 |
Completed |
National Cancer Institute (NCI) |
NA |
| NCT00079105 |
A Phase II Study VEPEMB In Patients With Hodgkin’s Lymphoma Aged ≥ 60 Years |
https://ClinicalTrials.gov/show/NCT00079105 |
Completed |
Newcastle-upon-Tyne Hospitals NHS Trust |
2010-12-31 |
| NCT00078858 |
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT00078858 |
Completed |
Fred Hutchinson Cancer Research Center |
2006-01-31 |
| NCT00004908 |
Radiation Therapy and Cyclophosphamide Plus Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin’s Disease or Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00004908 |
Completed |
Northwestern University |
2002-06-30 |
| NCT00004171 |
Peripheral Stem Cell Transplantation Following Radiation Therapy in Treating Patients With Hodgkin’s Disease or Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00004171 |
Completed |
Northwestern University |
2002-06-30 |
| NCT00077155 |
Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma |
https://ClinicalTrials.gov/show/NCT00077155 |
Completed |
National Cancer Institute (NCI) |
2010-06-30 |
| NCT00002561 |
Radiation Therapy and Chemotherapy in Treating Patients With Hodgkin’s Disease |
https://ClinicalTrials.gov/show/NCT00002561 |
Completed |
Canadian Cancer Trials Group |
2011-08-15 |
| NCT00072514 |
Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies |
https://ClinicalTrials.gov/show/NCT00072514 |
Completed |
Fred Hutchinson Cancer Research Center |
2008-07-31 |
| NCT00003210 |
Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin’s Lymphoma or Hodgkin’s Disease |
https://ClinicalTrials.gov/show/NCT00003210 |
Completed |
National Cancer Institute (NCI) |
2003-11-30 |
| NCT00003114 |
Combination Chemotherapy in Treating Patients With AIDS-Related Hodgkin’s Disease |
https://ClinicalTrials.gov/show/NCT00003114 |
Completed |
Case Comprehensive Cancer Center |
2002-06-30 |
| NCT00014209 |
Combination Chemotherapy in Hodgkin’s Disease or Non-Hodgkin’s Lymphoma Not Responding to Previous Treatment |
https://ClinicalTrials.gov/show/NCT00014209 |
Completed |
Canadian Cancer Trials Group |
2002-07-15 |
| NCT00062868 |
LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma |
https://ClinicalTrials.gov/show/NCT00062868 |
Completed |
Baylor College of Medicine |
2014-04-30 |
| NCT00061672 |
Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma |
https://ClinicalTrials.gov/show/NCT00061672 |
Completed |
Abbott |
NA |
| NCT00795769 |
Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT00795769 |
Completed |
Fred Hutchinson Cancer Research Center |
2009-06-09 |
| NCT00060372 |
Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer |
https://ClinicalTrials.gov/show/NCT00060372 |
Completed |
National Cancer Institute (NCI) |
2008-04-30 |
| NCT00058617 |
Epstein Barr Virus (EBV) Specific Cytotoxic T-Cells, Relapsed Lymphoma, ANGEL |
https://ClinicalTrials.gov/show/NCT00058617 |
Completed |
Baylor College of Medicine |
2011-08-31 |
| NCT00049504 |
Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00049504 |
Completed |
Fred Hutchinson Cancer Research Center |
2011-03-31 |
| NCT00040846 |
Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT00040846 |
Completed |
Fred Hutchinson Cancer Research Center |
2009-12-31 |
| NCT00027820 |
Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer |
https://ClinicalTrials.gov/show/NCT00027820 |
Completed |
Fred Hutchinson Cancer Research Center |
2004-09-30 |
| NCT00025662 |
Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS |
https://ClinicalTrials.gov/show/NCT00025662 |
Completed |
National Institutes of Health Clinical Center (CC) |
2008-02-29 |
| NCT00025415 |
Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction |
https://ClinicalTrials.gov/show/NCT00025415 |
Completed |
National Cancer Institute (NCI) |
2005-01-31 |
| NCT00025259 |
Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin’s Disease |
https://ClinicalTrials.gov/show/NCT00025259 |
Completed |
Children’s Oncology Group |
2012-08-31 |
| NCT00014235 |
Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00014235 |
Completed |
Fred Hutchinson Cancer Research Center |
2005-02-28 |
| NCT00005811 |
Topotecan Hydrochloride in Treating Children With Meningeal Cancer That Has Not Responded to Previous Treatment |
https://ClinicalTrials.gov/show/NCT00005811 |
Completed |
National Cancer Institute (NCI) |
2006-04-30 |
| NCT00005803 |
Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma |
https://ClinicalTrials.gov/show/NCT00005803 |
Completed |
Fred Hutchinson Cancer Research Center |
2016-01-31 |
| NCT00004241 |
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma |
https://ClinicalTrials.gov/show/NCT00004241 |
Completed |
National Cancer Institute (NCI) |
2006-05-31 |
| NCT00003970 |
Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma |
https://ClinicalTrials.gov/show/NCT00003970 |
Completed |
National Cancer Institute (NCI) |
2003-10-31 |
| NCT00003820 |
Rituximab in Treating Patients With Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00003820 |
Completed |
Stanford University |
2008-08-31 |
| NCT00003741 |
Monoclonal Antibody Therapy in Treating Patients With Refractory Anaplastic Large Cell Lymphoma or Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00003741 |
Completed |
National Cancer Institute (NCI) |
NA |
| NCT00051597 |
A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00051597 |
Completed |
Seattle Genetics, Inc. |
NA |
| NCT00039910 |
Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia |
https://ClinicalTrials.gov/show/NCT00039910 |
Completed |
Pfizer |
NA |
| NCT00038558 |
Prophylactic Use of Filgrastim SD/01 in Patients With Hodgkin’s Disease Receiving ABVD Chemotherapy |
https://ClinicalTrials.gov/show/NCT00038558 |
Completed |
M.D. Anderson Cancer Center |
2004-02-29 |
| NCT00026208 |
Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00026208 |
Completed |
Stanford University |
2013-04-26 |
| NCT00000626 |
Phase II Study of Filgrastim (G-CSF) Plus ABVD in the Treatment of HIV-Associated Hodgkin’s Disease |
https://ClinicalTrials.gov/show/NCT00000626 |
Completed |
National Institute of Allergy and Infectious Diseases (NIAID) |
NA |
| NCT00005799 |
Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer |
https://ClinicalTrials.gov/show/NCT00005799 |
Completed |
Fred Hutchinson Cancer Research Center |
2002-07-31 |
| NCT00165269 |
Mantle Irradiation for Hodgkin’s Disease |
https://ClinicalTrials.gov/show/NCT00165269 |
Completed |
Dana-Farber Cancer Institute |
2000-06-30 |
| NCT00001830 |
Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants |
https://ClinicalTrials.gov/show/NCT00001830 |
Completed |
National Institutes of Health Clinical Center (CC) |
NA |
| NCT00001575 |
Anti-Tac(90 Y-HAT) to Treat Hodgkin’s Disease, Non-Hodgkin’s Lymphoma and Lymphoid Leukemia |
https://ClinicalTrials.gov/show/NCT00001575 |
Completed |
National Institutes of Health Clinical Center (CC) |
2013-11-30 |
| NCT00001430 |
A Randomized Study of EPOCH II Versus EPOCH II and Immunotherapy in Lymphomas |
https://ClinicalTrials.gov/show/NCT00001430 |
Completed |
National Institutes of Health Clinical Center (CC) |
NA |